Remove 2001 Remove Biopharma Remove Leads
article thumbnail

EU pharmaceutical legislation revisions: what are the implications for biopharma?

European Pharmaceutical Review

1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. However, it is clear that changes are likely to have meaningful impacts for biopharma players if adopted.

article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

1 However, as most biosimilars are developed by means of a complex biotechnological process in living organisms, this inevitably leads to differences between the biosimilar and the reference product. Marie Manley leads Sidley’s Life Sciences team in London and is a distinguished thought leader and adviser on EU and UK regulatory law.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

PM360 Announces 2023 Trailblazer Award Winners

PM360

In total, PM360 , a leading life sciences marketing industry trade publication, recognized 73 winners across eight overall categories: Companies of the Year, CEOs of the Year, Products of the Year, Marketer of the Year, Marketing Team of the Year, Lifetime Achievement, Brand Champions, and Initiatives. Braun Medical, Inc.

article thumbnail

PM360 Announces 2023 Trailblazer Award Finalists

PM360

PM360 , a leading life sciences marketing industry trade publication, established the Trailblazer Awards in 2009 to recognize and honor outstanding companies, marketers, marketing teams, brand managers, and initiatives that have demonstrated innovation and achieved incredible results in the life sciences. Braun Medical, Inc.

article thumbnail

Innovations & Challenges in Brain Health

PM360

One in three people is expected to develop a neurological condition in their lifetime, and neurological diseases are the leading cause of disability. From your work on the AstraMerck merger to your leadership at Alnylam, you’ve been in the biopharma industry for over 30 years. Today, the urgency has never been more apparent.

article thumbnail

Meet the company on a mission to transform research and advance healthcare

Pharmaceutical Technology

This may lead to therapies and dosing regimes being less suitable for minority populations – and according to Hans Bunschoten, chief strategy officer at clinical research company Cerba Research, part of Cerba Healthcare, this is a major problem. Hans Bunschoten: Viroclinics was founded in 2001, spun out of a university setting.